

2017 SESSION

INTRODUCED

17103740D

SENATE BILL NO. 1403

Offered January 11, 2017

Prefiled January 11, 2017

A BILL to require the Board of Pharmacy to deschedule or reschedule cannabidiol upon publication of an interim final rule.

Patron—Dunnavant

Referred to Committee on Education and Health

Be it enacted by the General Assembly of Virginia:

1. § 1. That within 90 days of publication in the Federal Register of an interim final rule issued pursuant to 21 U.S.C. § 811(j) descheduling or rescheduling cannabidiol or any product containing cannabidiol that has been approved as a prescription medication by the U.S. Food and Drug Administration pursuant to 21 U.S.C. § 360bb and 21 U.S.C. § 355 and notwithstanding the provisions of subsection A, B, or E of § 54.1-3443 of the Code of Virginia, the Board of Pharmacy shall similarly control the substance under the Drug Control Act (§ 54.1-3400 et seq. of the Code of Virginia) to reflect the new designation established by the U.S. Drug Enforcement Administration.

Within 90 days of publication of a final rule issued pursuant to 21 U.S.C. § 811(j) that differs from the interim final rule previously published and notwithstanding the provisions of subsection A, B, or E of § 54.1-3443 of the Code of Virginia, the Board of Pharmacy shall deschedule or reschedule cannabidiol or any product containing cannabidiol that has been approved as a prescription medication by the U.S. Food and Drug Administration pursuant to 21 U.S.C. § 360bb and 21 U.S.C. § 355 to conform to the final rule. The control of any substance under this section shall remain in effect until enacted into law in the Drug Control Act or until the Board of Pharmacy deschedules or reschedules such substance pursuant to the provisions of subsections A and B of § 54.1-3443 of the Code of Virginia.

INTRODUCED

SB1403